itraconazole

Summary

Summary: One of the triazole ANTIFUNGAL AGENTS that inhibits cytochrome P-450-dependent enzymes resulting in impairment of ERGOSTEROL synthesis. It has been used against histoplasmosis, blastomycosis, cryptococcal meningitis & aspergillosis.

Top Publications

  1. ncbi The safety and efficacy of itraconazole for the treatment of patients with eumycetoma due to Madurella mycetomatis
    A H Fahal
    Mycetoma Research Centre, University of Khartoum, Khartoum, Sudan
    Trans R Soc Trop Med Hyg 105:127-32. 2011
  2. pmc The antifungal drug itraconazole inhibits vascular endothelial growth factor receptor 2 (VEGFR2) glycosylation, trafficking, and signaling in endothelial cells
    Benjamin A Nacev
    Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    J Biol Chem 286:44045-56. 2011
  3. ncbi Treatment of cutaneous sporotrichosis with itraconazole--study of 645 patients
    Monica Bastos de Lima Barros
    Evandro Chagas Clinical Research Institute, Rio de Janeiro, Brazil
    Clin Infect Dis 52:e200-6. 2011
  4. pmc Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole
    A Espinel-Ingroff
    VCU Medical Center, Richmond, Virginia, USA
    Antimicrob Agents Chemother 56:5898-906. 2012
  5. pmc Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth
    James Kim
    Department of Developmental Biology, Stanford University, Stanford, CA 94305, USA
    Cancer Cell 17:388-99. 2010
  6. pmc Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists
    James Kim
    Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, CA 94305, USA
    Cancer Cell 23:23-34. 2013
  7. ncbi Melanin biosynthesis in Madurella mycetomatis and its effect on susceptibility to itraconazole and ketoconazole
    Wendy W J van de Sande
    Erasmus MC, University Medical Centre Rotterdam, Department of Medical Microbiology and Infectious Diseases, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands
    Microbes Infect 9:1114-23. 2007
  8. ncbi Development of a binary lipid nanoparticles formulation of itraconazole for parenteral administration and controlled release
    Jin Ki Kim
    Laboratory of Excellency for Drug and Gene Delivery, College of Pharmacy, Seoul National University, 599 Gwanak Ro, Gwanak Gu, Seoul 151 742, Republic of Korea
    Int J Pharm 383:209-15. 2010
  9. pmc Multicenter evaluation of a new disk agar diffusion method for susceptibility testing of filamentous fungi with voriconazole, posaconazole, itraconazole, amphotericin B, and caspofungin
    A Espinel-Ingroff
    Virginia Commonwealth University Medical Center, Richmond, VA 23298 0049, USA
    J Clin Microbiol 45:1811-20. 2007
  10. ncbi Induction of cytochrome P450 1A1 by ketoconazole and itraconazole but not fluconazole in murine and human hepatoma cell lines
    Hesham M Korashy
    Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada T6G 2N8
    Toxicol Sci 97:32-43. 2007

Research Grants

  1. Development of a new Imaging Platform for Pharmaceutical and Biomedical applicati
    Lynne S Taylor; Fiscal Year: 2012
  2. Acyclic Cucurbit n uril Molecular Containers for Drug Solubilization and Delivery
    LYLE D ISAACS; Fiscal Year: 2013
  3. THE YEAST ERGOSTEROL PATHWAY
    Martin Bard; Fiscal Year: 2007
  4. YEAST ERGOSTEROL PATHWAY--NEW ANTIFUNGAL TARGET SITES
    Martin Bard; Fiscal Year: 1999
  5. TRICHOPHYTON AND ASPERGILLUS IMMUNOLOGY AND LUNG DISEASE
    Thomas Platts Mills; Fiscal Year: 1999
  6. REDUCED DRUG INTERACTIONS OF AZOLE ANTIFUNGAL DRUGS
    Joseph Gal; Fiscal Year: 2003
  7. Planning a Multicenter Oral Itraconazole Trial in Chronic Rhinosinusitis Patients
    Hirohito Kita; Fiscal Year: 2007
  8. Antifungal Drug Resistance in Aspergillus
    Kieren Marr; Fiscal Year: 2004
  9. ADULT AIDS CLINICAL TRIALS GROUP
    Michael Saag; Fiscal Year: 2007
  10. RECENT ADVANCES IN AIDS AND HIV RESEARCH
    Michael Saag; Fiscal Year: 2007

Detail Information

Publications280 found, 100 shown here

  1. ncbi The safety and efficacy of itraconazole for the treatment of patients with eumycetoma due to Madurella mycetomatis
    A H Fahal
    Mycetoma Research Centre, University of Khartoum, Khartoum, Sudan
    Trans R Soc Trop Med Hyg 105:127-32. 2011
    This prospective study aimed to determine the safety and efficacy of itraconazole for the treatment of patients with mycetoma due to Madurella mycetomatis...
  2. pmc The antifungal drug itraconazole inhibits vascular endothelial growth factor receptor 2 (VEGFR2) glycosylation, trafficking, and signaling in endothelial cells
    Benjamin A Nacev
    Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    J Biol Chem 286:44045-56. 2011
    b>Itraconazole is a safe and widely used antifungal drug that was recently found to possess potent antiangiogenic activity. Currently, there are four active clinical trials evaluating itraconazole as a cancer therapeutic...
  3. ncbi Treatment of cutaneous sporotrichosis with itraconazole--study of 645 patients
    Monica Bastos de Lima Barros
    Evandro Chagas Clinical Research Institute, Rio de Janeiro, Brazil
    Clin Infect Dis 52:e200-6. 2011
    b>Itraconazole has become the first choice for treatment of cutaneous sporotrichosis. However, this recommendation is based on case reports and small series...
  4. pmc Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole
    A Espinel-Ingroff
    VCU Medical Center, Richmond, Virginia, USA
    Antimicrob Agents Chemother 56:5898-906. 2012
    ..cutoff values (ECVs) for the Cryptococcus neoformans-Cryptococcus gattii species complex versus fluconazole, itraconazole, posaconazole, and voriconazole are not available...
  5. pmc Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth
    James Kim
    Department of Developmental Biology, Stanford University, Stanford, CA 94305, USA
    Cancer Cell 17:388-99. 2010
    In a screen of drugs previously tested in humans we identified itraconazole, a systemic antifungal, as a potent antagonist of the Hedgehog (Hh) signaling pathway that acts by a mechanism distinct from its inhibitory effect on fungal ..
  6. pmc Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists
    James Kim
    Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, CA 94305, USA
    Cancer Cell 23:23-34. 2013
    ..Here, we report that itraconazole and arsenic trioxide, two agents in clinical use that inhibit Hedgehog signaling by mechanisms distinct from ..
  7. ncbi Melanin biosynthesis in Madurella mycetomatis and its effect on susceptibility to itraconazole and ketoconazole
    Wendy W J van de Sande
    Erasmus MC, University Medical Centre Rotterdam, Department of Medical Microbiology and Infectious Diseases, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands
    Microbes Infect 9:1114-23. 2007
    ..When melanin was added to the culture medium, MICs were found to be 16-fold elevated in the case of itraconazole and 32-fold for ketoconazole. MICs for amphotericin B, fluconazole and voriconazole were not affected...
  8. ncbi Development of a binary lipid nanoparticles formulation of itraconazole for parenteral administration and controlled release
    Jin Ki Kim
    Laboratory of Excellency for Drug and Gene Delivery, College of Pharmacy, Seoul National University, 599 Gwanak Ro, Gwanak Gu, Seoul 151 742, Republic of Korea
    Int J Pharm 383:209-15. 2010
    The principal aim of this study was to develop an intravenous formulation of itraconazole (ITZ) using lipid nanoparticles based on binary mixture of liquid and solid lipids...
  9. pmc Multicenter evaluation of a new disk agar diffusion method for susceptibility testing of filamentous fungi with voriconazole, posaconazole, itraconazole, amphotericin B, and caspofungin
    A Espinel-Ingroff
    Virginia Commonwealth University Medical Center, Richmond, VA 23298 0049, USA
    J Clin Microbiol 45:1811-20. 2007
    ..MH] agar), (ii) three incubation times (16 to 24, 48, and 72 h), and (iii) seven disks (amphotericin B and itraconazole 10-microg disks, voriconazole 1- and 10-microg disks, two sources of caspofungin 5-microg disks [BBL and Oxoid],..
  10. ncbi Induction of cytochrome P450 1A1 by ketoconazole and itraconazole but not fluconazole in murine and human hepatoma cell lines
    Hesham M Korashy
    Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada T6G 2N8
    Toxicol Sci 97:32-43. 2007
    ..Therefore, we examined here the ability of three structurally different antifungal drugs, ketoconazole (KTZ), itraconazole (ITZ), and fluconazole (FLZ) to induce the CYP1A1, an enzyme known to play an important role in chemical ..
  11. pmc In vitro susceptibilities of Madurella mycetomatis to itraconazole and amphotericin B assessed by a modified NCCLS method and a viability-based 2,3-Bis(2-methoxy-4-nitro-5- sulfophenyl)-5-[(phenylamino)carbonyl]-2H-tetrazolium hydroxide (XTT) assay
    Abdalla O A Ahmed
    Mycetoma Research Group, Institute of Endemic Diseases, University of Khartoum, Khartoum, Sudan
    Antimicrob Agents Chemother 48:2742-6. 2004
    Susceptibilities of Madurella mycetomatis against amphotericin B and itraconazole in vitro were determined by protocols based on NCCLS guidelines (visual reading) and a 2,3-bis (2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino) carbonyl]-..
  12. pmc Multiple resistance mechanisms among Aspergillus fumigatus mutants with high-level resistance to itraconazole
    Adriana M Nascimento
    Departamento de Genetica, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo, Sao Paulo, Brazil
    Antimicrob Agents Chemother 47:1719-26. 2003
    A collection of Aspergillus fumigatus mutants highly resistant to itraconazole (RIT) at 100 micro g ml(-1) were selected in vitro (following UV irradiation as a preliminary step) to investigate mechanisms of drug resistance in this ..
  13. ncbi Randomized trial with itraconazole, ketoconazole and sulfadiazine in paracoccidioidomycosis
    M A Shikanai-Yasuda
    Department of Infectious and Parasitic Diseases, School of Medicine, Sao Paulo University, Brazil
    Med Mycol 40:411-7. 2002
    Forty-two patients with active paracoccidioidomycosis were randomized to receive itraconazole (50-100 mg d(-1)), ketoconazole (200-400 mg d(-1)) or sulfadiazine (100-150 mg kg d(-1) up to 6 g d(-1)) for 4-6 months, followed by slow ..
  14. ncbi Efficacy and safety of intravenous itraconazole as empirical antifungal therapy for persistent fever in neutropenic patients with hematological malignancies in Japan
    Kensuke Ohta
    Department of Hematology, Saiseikai Nakatsu Hospital Osaka, Osaka, Japan
    Int J Hematol 89:649-55. 2009
    Recently, empirical antifungal therapy with intravenous itraconazole (ITCZ) for neutropenic patients with antibiotics-resistant fever has been approved by Japanese Ministry of Health, Labour and Welfare on the bases of previous ..
  15. ncbi Characterization of the interaction of 2-hydroxypropyl-beta-cyclodextrin with itraconazole at pH 2, 4, and 7
    Jef Peeters
    Department of Drug Delivery Research, Johnson and Johnson Pharmaceutical Research and Development, Beerse 2340, Belgium
    J Pharm Sci 91:1414-22. 2002
    Phase-solubility techniques were used to assess the effect of pH on itraconazole complexation with 2-hydroxypropyl-beta-cyclodextrin (HPbetaCD)...
  16. pmc A novel itraconazole bioadhesive film for vaginal delivery: design, optimization, and physicodynamic characterization
    Nitin B Dobaria
    Pharmacy Department, Centre of Relevance and Excellence in Novel Drug Delivery Systems, The MS University of Baroda, Vadodara 390 002, India
    AAPS PharmSciTech 10:951-9. 2009
    ..b>Itraconazole was formulated in bioadhesive film formulations that could be retained in the vagina for prolonged intervals...
  17. ncbi Toxicodynamics of itraconazole: implications for therapeutic drug monitoring
    Jodi M Lestner
    The University of Manchester, Manchester Academic Health Science Centre, NIHR Translational Research Facility in Respiratory Medicine, University Hospital of South Manchester NHS Foundation Trust, Manchester, UK
    Clin Infect Dis 49:928-30. 2009
    We explored concentration-toxicity relationships for itraconazole among 216 patients. Logistic regression revealed a progressive increase in the probability of toxicity with increasing concentrations of itraconazole...
  18. ncbi Inhibition of angiogenesis by the antifungal drug itraconazole
    Curtis R Chong
    Department of Pharmacology and Molecular Sciences, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
    ACS Chem Biol 2:263-70. 2007
    ..One of the most promising and unexpected hits was itraconazole, a known antifungal drug...
  19. ncbi Cutaneous leishmaniasis: successful treatment with itraconazole
    Javier Consigli
    Department of Dermatology, Hospital Cordoba, Argentina
    Int J Dermatol 45:46-9. 2006
    ..Antimonial drugs are the mainstay treatment for all the clinical forms of the disease. Amphotericin B is the second-choice drug...
  20. pmc Synergistic inhibition of endothelial cell proliferation, tube formation, and sprouting by cyclosporin A and itraconazole
    Benjamin A Nacev
    Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America
    PLoS ONE 6:e24793. 2011
    ..Our screen identified cyclosporin A (CsA), an immunosuppressant, and itraconazole, an antifungal drug, as a synergistic pair of inhibitors of endothelial cell proliferation...
  21. ncbi Development of an itraconazole-loaded nanostructured lipid carrier (NLC) formulation for pulmonary application
    J Pardeike
    Institute of Pharmaceutical Sciences, Department of Pharmaceutical Technology, Karl Franzens Universitat Graz, Universitatsplatz 1, 8010 Graz, Austria
    Int J Pharm 419:329-38. 2011
    b>Itraconazole-loaded NLC for pulmonary application were developed. In Precirol ATO 5 and oleic acid Itraconazole had the highest solubility...
  22. ncbi Intravenous itraconazole emulsions produced by SolEmuls technology
    Aslihan Akkar
    Department of Pharmaceutical Technology, Biotechnology and Quality Management, Free University of Berlin, Berlin, Germany
    Eur J Pharm Biopharm 56:29-36. 2003
    b>Itraconazole is a drug which is poorly soluble in both the water and oil phases of emulsions. Incorporation in parenteral emulsions was performed applying the SolEmuls Technology, i.e...
  23. ncbi Eumycetoma caused by Cladophialophora bantiana successfully treated with itraconazole
    Alexandro Bonifaz
    Dermatology Service and Mycology Department, General Hospital of Mexico, Del Valle, Mexico
    Med Mycol 47:111-4. 2009
    ..Clinical and mycologic cure was achieved after 20 months of treatment with itraconazole at a starting dose of 300 mg/day that was tapered during the course of therapy...
  24. ncbi Antifungal susceptibility testing of Exophiala spp.: a head-to-head comparison of amphotericin B, itraconazole, posaconazole and voriconazole
    Annette W Fothergill
    University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229 3900, USA
    Med Mycol 47:41-3. 2009
    ..we tested 160 clinical isolates against amphotericin B, itraconazole, posaconazole, and voriconazole in a head-to-head comparison...
  25. pmc Phase 2 study of pemetrexed and itraconazole as second-line therapy for metastatic nonsquamous non-small-cell lung cancer
    Charles M Rudin
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1550 Orleans Street, Baltimore, MD 21231, USA
    J Thorac Oncol 8:619-23. 2013
    Preclinical studies have suggested that the oral antifungal agent itraconazole specifically inhibits proliferation, migration, and tube formation of endothelial cells...
  26. ncbi Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma
    Daniel J Kim
    Daniel J Kim, James Kim, Katrina Spaunhurst, Rita Khodosh, Kalyani Chandra, Teresa Fu, Philip A Beachy, and Jean Y Tang, Stanford University, Stanford Anita Gilliam, Palo Alto Medical Foundation, Palo Alto, CA James Kim, University of Texas Southwestern, Dallas, TX Javier Montoya and Monserrat Molgo, Universidad Catolica de Chile, Santiago, Chile
    J Clin Oncol 32:745-51. 2014
    b>Itraconazole, a US Food and Drug Administration-approved antifungal drug, inhibits the Hedgehog (HH) signaling pathway, a crucial driver of basal cell carcinoma (BCC) tumorigenesis, and reduces BCC growth in mice...
  27. ncbi In vitro antifungal activity and toxicity of itraconazole in DMSA-PLGA nanoparticles
    Elaine P Cunha-Azevedo
    Biological Sciences Institute, Universidade de Brasilia, Brasilia DF 70910 900, Brazil
    J Nanosci Nanotechnol 11:2308-14. 2011
    b>Itraconazole (ITZ) is a drug used to treat various fungal infections and may cause side effects...
  28. pmc Itraconazole inhibits angiogenesis and tumor growth in non-small cell lung cancer
    Blake T Aftab
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, USA
    Cancer Res 71:6764-72. 2011
    ..A recent screen for selective inhibitors of endothelial cell proliferation identified the oral antifungal drug itraconazole as a novel agent with potential antiangiogenic activity...
  29. pmc Repurposing itraconazole as a treatment for advanced prostate cancer: a noncomparative randomized phase II trial in men with metastatic castration-resistant prostate cancer
    Emmanuel S Antonarakis
    Prostate Cancer Research Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, CRB1 1M45, Baltimore, Maryland 21231 1000, USA
    Oncologist 18:163-73. 2013
    The antifungal drug itraconazole inhibits angiogenesis and Hedgehog signaling and delays tumor growth in murine prostate cancer xenograft models...
  30. pmc In vitro comparative efficacy of voriconazole and itraconazole against fluconazole-susceptible and -resistant Cryptococcus neoformans isolates
    M H Nguyen
    Department of Medicine, University of Florida College of Medicine, and VA Medical Center, Gainesville 32610, USA
    Antimicrob Agents Chemother 42:471-2. 1998
    ..for 50 clinical isolates of fluconazole-susceptible or -resistant Cryptococcus neoformans was performed with itraconazole and voriconazole...
  31. ncbi Comparison of bioavailability of amorphous versus crystalline itraconazole nanoparticles via pulmonary administration in rats
    Wei Yang
    Division of Pharmaceutics, University of Texas at Austin, Austin, TX, USA
    Eur J Pharm Biopharm 75:33-41. 2010
    ..The nanocrystalline formulations of itraconazole (ITZ) were made by wet milling (i.e...
  32. ncbi Effects of itraconazole on the pharmacokinetics and pharmacodynamics of intravenously and orally administered oxycodone
    Teijo I Saari
    Department of Anesthesiology, University of Turku, Finland
    Eur J Clin Pharmacol 66:387-97. 2010
    The aim of this study was to investigate the effects of the cytochrome P450 3A4 (CYP34A) inhibitor itraconazole on the pharmacokinetics and pharmacodynamics of orally and intravenously administered oxycodone.
  33. pmc Pharmacokinetics and safety of a 7-day administration of intravenous itraconazole followed by a 14-day administration of itraconazole oral solution in patients with hematologic malignancy
    M A Boogaerts
    Department of Hematology, University Hospital Gasthuisberg, Leuven, Belgium
    Antimicrob Agents Chemother 45:981-5. 2001
    The pharmacokinetics and safety of an intravenous hydroxypropyl-beta-cyclodextrin solution of itraconazole administered for 7 days followed by itraconazole oral solution administered at 200 mg once or twice daily for 14 days were assessed ..
  34. ncbi A randomized, double-blind, placebo-controlled study of itraconazole capsules for the prevention of deep fungal infections in immunodeficient patients with HIV infection
    D E Smith
    National Centre in HIV Epidemiology and Clinical Research, Faculty of Medicine, University of New South Wales, Australia
    HIV Med 2:78-83. 2001
    To determine whether systemic or deep fungal infections can be prevented, a double-blind, placebo-controlled, phase III trial of itraconazole prophylaxis was undertaken in HIV-infected patients.
  35. ncbi Characterization of solid dispersions of itraconazole and hydroxypropylmethylcellulose prepared by melt extrusion, Part II
    Karel Six
    Laboratorium voor Farmacotechnologie en Biofarmacie, K U Leuven, Leuven, Belgium
    Pharm Res 20:1047-54. 2003
    This study was done to elucidate the physical and pharmaceutical properties of itraconazole-HPMC dispersions and the influence of water on the phase separation.
  36. pmc High prevalence of azole-resistant Aspergillus fumigatus in adults with cystic fibrosis exposed to itraconazole
    Pierre Regis Burgel
    Universite Paris Descartes, Sorbonne Paris Cité, Paris, France
    Antimicrob Agents Chemother 56:869-74. 2012
    Aspergillus fumigatus is the most frequent fungus found in the sputum of cystic fibrosis (CF) subjects. Itraconazole is prescribed for allergic bronchopulmonary aspergillosis (ABPA) or Aspergillus bronchitis in CF subjects...
  37. ncbi Itraconazole prophylaxis for fungal infections in patients with advanced human immunodeficiency virus infection: randomized, placebo-controlled, double-blind study. National Institute of Allergy and Infectious Diseases Mycoses Study Group
    D S McKinsey
    University of Missouri Kansas City School of Medicine, and Kansas City AIDS Research Consortium, USA
    Clin Infect Dis 28:1049-56. 1999
    ..trial, 149 patients with advanced human immunodeficiency virus (HIV) infection were randomized to receive itraconazole capsules (200 mg daily) and 146 to receive a matched placebo...
  38. pmc Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation
    David I Marks
    University Hospitals Bristol NHS Foundation Trust, Bristol, UK
    Br J Haematol 155:318-27. 2011
    ..open-label, multicentre study compared the efficacy and safety of voriconazole (234 patients) versus itraconazole (255 patients) in alloHCT recipients...
  39. pmc In vitro activities of terbinafine against Aspergillus species in comparison with those of itraconazole and amphotericin B
    C B Moore
    Department of Microbiology, Hope Hospital, Salford, United Kingdom
    Antimicrob Agents Chemother 45:1882-5. 2001
    Compared with the in vitro activities of itraconazole (geometric mean MIC [GM], 0.56 microg/ml) and amphotericin B (GM, 0.66 microg/ml), the in vitro activity of terbinafine was inferior against Aspergillus fumigatus (GM, 19...
  40. pmc Comparison of visual and spectrophotometric methods of broth microdilution MIC end point determination and evaluation of a sterol quantitation method for in vitro susceptibility testing of fluconazole and itraconazole against trailing and nontrailing Cand
    Beth A Arthington-Skaggs
    Mycotic Diseases Branch, Division of Bacterial and Mycotic Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Atlanta, GA 30333, USA
    Antimicrob Agents Chemother 46:2477-81. 2002
    ..determine the incidence of trailing growth, we performed testing of in vitro susceptibility to fluconazole and itraconazole using the National Committee for Clinical Laboratory Standards broth microdilution M27-A reference procedure ..
  41. ncbi Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay
    Kieren A Marr
    Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    Clin Infect Dis 40:1762-9. 2005
    ..Reported sensitivity of the galactomannan enzyme immunoassay as an early diagnostic test for invasive aspergillosis (IA) has been widely variable, ranging from 29% to 100% in earlier clinical studies...
  42. ncbi Terbinafine versus itraconazole and fluconazole in the treatment of Vulvovaginal candidiasis
    Ayten Ferahbas
    Department of Dermatology, Erciyes University, Medical Faculty, Kayseri, Turkey
    Am J Ther 13:332-6. 2006
    ..to determine in vivo and in vitro effectiveness of the 3 systemic antifungal agents: terbinafine and 2 azoles (itraconazole and fluconazole) in the treatment of patients with Vulvovaginal candidiasis...
  43. ncbi Combined itraconazole-pentoxifylline treatment promptly reduces lung fibrosis induced by chronic pulmonary paracoccidioidomycosis in mice
    Tonny W Naranjo
    Unidad de Micología Médica y Experimental, Corporacion para Investigaciones Biologicas, Medellin, Colombia
    Pulm Pharmacol Ther 24:81-91. 2011
    ..Our objective was to investigate the possible beneficial effects that a combined antifungal (Itraconazole) and immunomodulatory (Pentoxifylline) therapy would have in the development of fibrosis in a model of ..
  44. pmc Pharmacokinetic drug interactions with vandetanib during coadministration with rifampicin or itraconazole
    Paul Martin
    AstraZeneca, Alderley Park, Macclesfield, Cheshire, UK
    Drugs R D 11:37-51. 2011
    ..Clinical studies were performed to assess the potential for 3A4 inhibitors and inducers to affect exposure to vandetanib...
  45. ncbi Cushing's syndrome due to interaction between inhaled corticosteroids and itraconazole
    Mark J Bolland
    Department of Endocrinology, Auckland Hospital, Auckland, New Zealand
    Ann Pharmacother 38:46-9. 2004
    To report a case of an interaction between inhaled corticosteroids and itraconazole causing iatrogenic Cushing's syndrome and provide a review of the relevant literature.
  46. ncbi Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: a meta-analysis of randomised-controlled trials
    Konstantinos Z Vardakas
    Alfa Institute of Biomedical Sciences AIBS, Athens, Greece
    Br J Haematol 131:22-8. 2005
    Fluconazole and itraconazole are used as antifungal prophylaxis in neutropenic patients with haematological malignancies...
  47. ncbi An open-label comparative pilot study of oral voriconazole and itraconazole for long-term treatment of paracoccidioidomycosis
    Flavio Queiroz-Telles
    Department of Community Health, Hospital de Clinicas de Curitiba Universidade Federal do Paraná, Curitiba, Parana, Brazil
    Clin Infect Dis 45:1462-9. 2007
    In previous studies, itraconazole was revealed to be an effective therapy and was considered to be the gold standard treatment for mild-to-moderate acute and chronic clinical forms of paracoccidioidomycosis...
  48. ncbi A new self-emulsifying formulation of itraconazole with improved dissolution and oral absorption
    Ji Yeon Hong
    College of Pharmacy, Seoul National University, San 56 1, Sillim dong, Gwanak Gu, Seoul, 151 742, Republic of Korea
    J Control Release 110:332-8. 2006
    To enhance the dissolution and oral absorption of poorly water-soluble itraconazole, self-emulsifying drug delivery system (SEDDS) composed of oil, surfactant and cosurfactant for oral administration of itraconazole was formulated, and ..
  49. ncbi Itraconazole prophylaxis in pediatric cancer patients receiving conventional chemotherapy or autologous stem cell transplants
    Arne Simon
    Department of Pediatric Hematology Oncology, Children s Hospital, Medical Center University of Bonn, Adenauerallee 119, 53113, Bonn, Germany
    Support Care Cancer 15:213-20. 2007
    ..5 to 0.99/1,000 inpatient days in 2001. As a direct response to this increased environmental risk, itraconazole (ITC) was administered for primary prophylaxis in pediatric cancer patients for whom a particular high risk of ..
  50. ncbi Fluconazole and itraconazole susceptibility of vaginal yeast isolates from Slovakia
    Monika Sojakova
    1st Department of Obstetrics and Gynecology, Faculty of Medicine, Comenius University, Zochova 7, 811 03 Bratislava, Slovak Republic
    Mycopathologia 157:163-9. 2004
    ..in the vagina of patients treated in the gynecology clinic and tested in vitro activities of fluconazole and itraconazole against 227 clinical yeast isolates by the NCCLS microdilution method. C. albicans (87...
  51. ncbi Reduced food-effect and enhanced bioavailability of a self-microemulsifying formulation of itraconazole in healthy volunteers
    Jong Soo Woo
    Pharmaceutical Research Center, Hanmi Pharm Co, Ltd, Paltan myeon, 893 5 Hwaseong si, Gyeonggi Do, 445 913, Republic of Korea
    Eur J Pharm Sci 33:159-65. 2008
    ..This study was designed to compare the oral bioavailability and food-effect of SMEDDS of itraconazole (ITRA-GSMP capsule containing 50mg itraconazole) to that of the currently marketed formulation (Sporanox ..
  52. ncbi Anti-inflammatory effect of itraconazole in stable allergic bronchopulmonary aspergillosis: a randomized controlled trial
    Peter Alexander Blanch Wark
    Faculty of Health, University of Newcastle, and the Department of Respiratory and Sleep Medicine and the Airways Infection and Immunology Research Group, John Hunter Hospital, Newcastle, Australia
    J Allergy Clin Immunol 111:952-7. 2003
    ..Allergic bronchopulmonary aspergillosis (ABPA) complicates chronic asthma and results from hypersensitivity to the fungus Aspergillus fumigatu s, causing an intense systemic immune response and progressive lung damage...
  53. ncbi Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial. GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche dell'
    F Menichetti
    Istituto di Malattie Infettive, Universita di Perugia, Italy
    Clin Infect Dis 28:250-5. 1999
    To evaluate the efficacy and safety of itraconazole oral solution for preventing fungal infections, a randomized, placebo-controlled, double-blind, multicenter trial was conducted: 405 neutropenic patients with hematologic malignancies ..
  54. ncbi Transcriptional profiles of Trichophyton rubrum in response to itraconazole
    Youjiang Diao
    College of Animal Science and Veterinary Medicine, Jilin University, Changchun, PR China
    Med Mycol 47:237-47. 2009
    ..rubrum to itraconazole was studied by large-scale gene expression profiling...
  55. ncbi Residual pulmonary abnormalities in adult patients with chronic paracoccidioidomycosis: prolonged follow-up after itraconazole therapy
    A M Tobon
    Medical and Experimental Mycology Group, Corporacion para Investigaciones Biologicas, Medellin, Colombia
    Clin Infect Dis 37:898-904. 2003
    b>Itraconazole effectively controls active paracoccidioidomycosis but appears not to hinder lung fibrosis...
  56. ncbi A controlled trial of itraconazole as primary prophylaxis for systemic fungal infections in patients with advanced human immunodeficiency virus infection in Thailand
    Suwat Chariyalertsak
    Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
    Clin Infect Dis 34:277-84. 2002
    ..patients with HIV infection and CD4+ lymphocyte counts of <200 cells/microL were randomized to receive oral itraconazole (200 mg per day), and 66 similar patients received a matched placebo...
  57. ncbi Increasing the oral bioavailability of the poorly water soluble drug itraconazole with ordered mesoporous silica
    Randy Mellaerts
    Centre for Surface Chemistry and Catalysis, Catholic University of Leuven, Heverlee, Belgium
    Eur J Pharm Biopharm 69:223-30. 2008
    ..b>Itraconazole was selected as model compound...
  58. ncbi Increased expression of a novel Aspergillus fumigatus ABC transporter gene, atrF, in the presence of itraconazole in an itraconazole resistant clinical isolate
    John W Slaven
    School of Medicine, 1 800 Stopford Building, University of Manchester, Oxford Road, Manchester, UK
    Fungal Genet Biol 36:199-206. 2002
    Aspergillus fumigatus is the most frequent causative agent of invasive aspergillosis. Itraconazole became available in 1990 to treat invasive aspergillosis, but instances of resistance have now been described...
  59. pmc A point mutation in the 14alpha-sterol demethylase gene cyp51A contributes to itraconazole resistance in Aspergillus fumigatus
    T M Diaz-Guerra
    Unidad de Micologia, Centro Nacional de Microbiologia, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain
    Antimicrob Agents Chemother 47:1120-4. 2003
    The genes encoding 14alpha-sterol demethylases (cyp51A and cyp51B) were analyzed in 12 itraconazole (ITC)-resistant and three ITC-susceptible clinical isolates of Aspergillus fumigatus...
  60. ncbi Effect of hypoxic conditions on in vitro susceptibility testing of amphotericin B, itraconazole and micafungin against Aspergillus and Candida
    Peter A Warn
    School of Medicine, University of Manchester, Hope Hospital, Salford M6 8HD
    J Antimicrob Chemother 53:743-9. 2004
    The aim of this study was to investigate the effect of hypoxic conditions on in vitro susceptibility testing of amphotericin B, itraconazole and micafungin against Aspergillus (four species) and Candida (six species).
  61. ncbi Itraconazole oral solution and intravenous formulations: a review of pharmacokinetics and pharmacodynamics
    L Willems
    University Hospital Gasthuisberg, Herestraat 49, B 3000 Leuven, Belgium
    J Clin Pharm Ther 26:159-69. 2001
    b>Itraconazole is a triazole antifungal agent with a broad spectrum of activity. It is well tolerated and highly efficacious, particularly because its main metabolite, hydroxy-itraconazole, also has considerable antifungal activity...
  62. ncbi In vitro susceptibility of the seven Malassezia species to ketoconazole, voriconazole, itraconazole and terbinafine
    A K Gupta
    Division of Dermatology, Department of Medicine, Sunnybrook and Women s College Health Sciences Center Sunnybrook site and the University of Toronto, Canada
    Br J Dermatol 142:758-65. 2000
    ..03-64.0 microg/mL) of three azole drugs, ketoconazole, voriconazole and itraconazole, as well as the allylamine terbinafine, using the agar dilution method...
  63. pmc Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi
    D J Diekema
    Department of Internal Medicine, University of Iowa College of Medicine, Iowa City, IA 52242, USA
    J Clin Microbiol 41:3623-6. 2003
    We examined the in vitro activity of caspofungin, posaconazole, voriconazole, ravuconazole, itraconazole, and amphotericin B against 448 recent clinical mold isolates...
  64. ncbi Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol
    Helen C Swaisland
    AstraZeneca Pharmaceuticals, Macclesfield, UK
    Clin Pharmacokinet 44:1067-81. 2005
    ..Based on these findings, three clinical studies were carried out to investigate pharmacokinetic drug interactions in vivo with gefitinib...
  65. pmc Visceral Leishmaniasis treated with antimonials/paromomycin followed by itraconazole/miltefosine after standard therapy failures in a human immunodeficiency virus-infected patient
    Patricia Barragan
    Infectious Disease Service, Hospital Universitari de Bellvitge, L Hospitalet, Barcelona, Spain
    Am J Trop Med Hyg 83:10-2. 2010
    ..We report the case of a human immunodeficiency virus-1-infected patient who had several relapses of visceral leishmaniasis after treatment with standard therapies and responded to a combined therapy...
  66. pmc Intravenous itraconazole vs. amphotericin B deoxycholate for empirical antifungal therapy in patients with persistent neutropenic fever
    Sun Hee Park
    Department of Internal Medicine, The Catholic Hematopoietic Stem Cell Transplantation Center, The Catholic University of Korea College of Medicine, Seoul, Korea
    Korean J Intern Med 21:165-72. 2006
    ..The antifungal triazoles offer a potentially safer and effective treatment alternative to Amphotericin B dexoycholate...
  67. ncbi Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled tria
    M Boogaerts
    Department of Hematology, University Hospital Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium
    Ann Intern Med 135:412-22. 2001
    ..OBJECTIVE: To compare the efficacy and safety of itraconazole with those of amphotericin B as empirical antifungal therapy...
  68. ncbi Safety and efficacy of itraconazole compared to amphotericin B as empirical antifungal therapy for neutropenic fever in patients with haematological malignancy
    Ulrich Schuler
    Medizinische Klinik und Poliklinik I, Universitatsklinikum Dresden, Germany
    Onkologie 30:185-91. 2007
    Safety, tolerability and efficacy of itraconazole and amphotericin B (AMB) were compared for empirical antifungal treatment of febrile neutropenic cancer patients.
  69. ncbi Formulation and evaluation of itraconazole via liquid crystal for topical delivery system
    D I Nesseem
    National Organization for Drug Control and Research, 51 Wezaret El Zeraa St, Agouza, Cairo, Egypt
    J Pharm Biomed Anal 26:387-99. 2001
    ..stearyl ether/ oil and water form liquid crystalline system cream, which has a potential as dosage form for 1% itraconazole as topical dermal drug delivery...
  70. ncbi Conversion of nanosuspensions into dry powders by spray drying: a case study
    Mahesh V Chaubal
    Baxter Healthcare Corporation, Route 120 and Wilson Rd, Round Lake, Illinois 60073, USA
    Pharm Res 25:2302-8. 2008
    ..This case study examines impact of various formulation and processing parameters on redispersibility of the spray dried nanoparticles...
  71. pmc Outbreak of fungemia among neonates caused by Candida haemulonii resistant to amphotericin B, itraconazole, and fluconazole
    Zia U Khan
    Department of Microbiology, Faculty of Medicine, Kuwait University, Safat 13110, Kuwait
    J Clin Microbiol 45:2025-7. 2007
    ..They were all resistant to amphotericin B, fluconazole, and itraconazole. This report highlights the emergence of C...
  72. ncbi Itraconazole or allopurinol in the treatment of chronic American trypanosomiasis: the results of clinical and parasitological examinations 11 years post-treatment
    W Apt
    Laboratorio de Parasitologia Básico Clínico, Programa de Biologia Celular y Molecular, Instituto de Ciencias Biomedicas, Facultad de Medicina, Universidad de Chile, Independencia 1027, P O Box 427, Santiago 3, Chile
    Ann Trop Med Parasitol 99:733-41. 2005
    Eleven years after they had been given itraconazole or allopurinol for the treatment of chronic American trypanosomiasis, 109 adult patients were checked for electrocardiographic abnormalities and evidence of Trypanosoma cruzi infection...
  73. ncbi Use of polymerase chain reaction (PCR) and hybridization assays to detect Trypanosoma cruzi in chronic chagasic patients treated with itraconazole or allopurinol
    Ines Zulantay
    Cellular and Molecular Biology Program, Biomedical Sciences Institute, Faculty of Medicine, University of Chile, Santiago, Chile
    Diagn Microbiol Infect Dis 48:253-7. 2004
    ..chagasic patients with negative xenodiagnosis (XD) after 6 years following completion of therapy with either itraconazole or allopurinol was assessed by polymerase chain reaction (PCR) and hybridization assays...
  74. ncbi Involvement of phenobarbital and SKF 525A in the hepatotoxicity of antifungal drugs itraconazole and fluconazole in rats
    N Somchit
    Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Selangor, Malaysia
    Drug Chem Toxicol 29:237-53. 2006
    b>Itraconazole and fluconazole are potent wide spectrum antifungal drugs. Both of these drugs induce hepatotoxicity clinically. The mechanism underlying the hepatotoxicity is unknown...
  75. ncbi Using itraconazole to clear Batrachochytrium dendrobatidis infection, and subsequent depigmentation of Alytes muletensis tadpoles
    T W J Garner
    Institute of Zoology, Zoological Society of London, Regent s Park, London NW1 4RY, UK
    Dis Aquat Organ 83:257-60. 2009
    ..Here we confirm that the antifungal itraconazole is an effective treatment for infection in larval Alytes muletensis...
  76. pmc Pharmacokinetics of itraconazole and hydroxyitraconazole in healthy subjects after single and multiple doses of a novel formulation
    J W Mouton
    Canisius Wilhelmina Ziekenhuis Nijmegen, Nijmegen, The Netherlands
    Antimicrob Agents Chemother 50:4096-102. 2006
    Originally, itraconazole for parenteral administration was licensed in a 40% hydroxypropyl-beta-cyclodextrin (HPBCD) solution for intravenous administration. A novel formulation, the NanoCrystal formulation (NCF), was prepared...
  77. ncbi The role of itraconazole in preventing and treating systemic fungal infections in immunocompromised patients
    M Potter
    Department of Haematology, Royal Free Hospital, London, UK
    Acta Haematol 111:175-80. 2004
    ..This paper reports the deliberations of an expert panel that considered the role of itraconazole. It concluded that itraconazole has an important role in the prophylaxis and treatment of SFIs whether proven ..
  78. pmc Effect of itraconazole on the pharmacokinetics and pharmacodynamics of a single oral dose of brotizolam
    T Osanai
    Clinical Research Center, Hirosaki University Hospital, Hirosaki, Japan
    Br J Clin Pharmacol 58:476-81. 2004
    To assess the effect of itraconazole, a potent inhibitor of cytochrome P450 (CYP)3A4, on the single oral dose pharmacokinetics and pharmacodynamics of brotizolam.
  79. ncbi Formulation and drying of miconazole and itraconazole nanosuspensions
    Ana M Cerdeira
    Cilag AG, Hochstrasse 201, 8205 Schaffhausen, Switzerland
    Int J Pharm 443:209-20. 2013
    Miconazole and itraconazole possess adequate membrane permeability, but only slight water solubility, which limits their bioavailability and antifungal effect...
  80. ncbi Evidence of significant contribution from CYP3A5 to hepatic drug metabolism
    Weili Huang
    Department of Pharmaceutics, Box 357610, University of Washington, Seattle, WA 98195 7610, USA
    Drug Metab Dispos 32:1434-45. 2004
    ..2-fold higher than those of group 1 (p < 0.05 for 5 of 8 substrates). After adjusting for CYP3A4 activity (itraconazole hydroxylation), mean product formation rates for group 2 microsomes were still significantly higher than those ..
  81. ncbi Efficacy of recombinant human mannose binding lectin alone and in combination with itraconazole against murine Candida albicans vaginitis
    Karl V Clemons
    California Institute for Medical Research, San Jose, California, USA
    Immunol Invest 40:553-68. 2011
    ..Intravenous treatment with rhMBL alone or in combination with oral itraconazole enhanced the clearance of C...
  82. ncbi Cutaneous protothecosis: report of a third Brazilian case
    Clarisse Zaitz
    Division of Dermatology, Department of Medicine, Santa Casa Medical School, Sao Paulo, Brazil
    Int J Dermatol 45:124-6. 2006
    ..We emphasize the mycological and pathological aspects of this infection that can lead to misdiagnosis. The patient was successfully treated with itraconazole.
  83. ncbi Formulation of parenteral microemulsion containing itraconazole
    Yun Seok Rhee
    College of Pharmacy, Sungkyunkwan University, Suwon 440 746, Korea
    Arch Pharm Res 30:114-23. 2007
    The aim of this study was to develop an aqueous parenteral formulation containing itraconazole (ITZ) using an o/w microemulsion system. A mixture of benzyl alcohol and medium chain triglyceride (3/1) was chosen as the oil phase...
  84. ncbi A rapid HPLC method with fluorometric detection for determination of plasma itraconazole and hydroxy-itraconazole concentrations in cystic fibrosis children with allergic bronchopulmonary aspergillosis
    Stefanie Redmann
    School of Pharmacy, The University of Queensland and the Australian Centre for Paediatric Pharmacokinetics, Mater Health Services, Brisbane, QLD, Australia
    Biomed Chromatogr 20:343-8. 2006
    ..rapid and selective high-performance liquid chromatography (HPLC) method is described for the quantitation of itraconazole and hydroxy-itraconazole in 100 microL of plasma from a paediatric population...
  85. ncbi Effects of cyclosporine A and itraconazole on permeability, biliary excretion and pharmacokinetics of amlodipine
    Liang Ni
    Center of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing 210009, China
    Drug Metab Lett 2:163-8. 2008
    Cyclosporin A (CsA) is a P-glycoprotein (P-gp) inhibitor clinically used as an immunosuppressant. Itraconazole (ITZ) functions as an inhibitor of both the P-gp and CYP3A and is used as a fungistatic/fungicidal agent in human and ..
  86. ncbi Effects of the antifungal agent itraconazole on proliferative changes of the forestomach mucosa in alloxan-induced diabetic rats
    Tomoya Sano
    Department of Pathology, Faculty of Pharmaceutical Sciences, Setsunan University, Osaka, Japan
    Toxicol Pathol 37:790-8. 2009
    ..Thus, the present study was conducted to examine the effects of the antifungal agent itraconazole (ITCZ) on proliferative and inflammatory changes of the forestomach in alloxan-induced diabetic WBN/Kob rats...
  87. ncbi Bioequivalence study of two formulations of 100 mg capsule of itraconazole. Quantification by tandem mass spectrometry
    Josélia Larger Manfio
    BIOCINESE Biopharmaceutical Studies Center, Toledo, PR, Brazil
    Arzneimittelforschung 60:157-61. 2010
    The purpose of this study is to compare the bioavailability of two itraconazole (CAS 84625-61-6) capsule formulations. An open, randomized, two-period crossover study with a 7-day washout interval was conduced in 32 healthy volunteers...
  88. pmc Chemotherapy with benznidazole and itraconazole for mice infected with different Trypanosoma cruzi clonal genotypes
    Max Jean de Ornelas Toledo
    Departamento Análises Clínicas, Centro de Ciencias da Saude, Universidade Estadual de Maringa, Maringa, Brazil
    Antimicrob Agents Chemother 47:223-30. 2003
    The benznidazole (BZ) and itraconazole (ITC) susceptibilities of a standard set of Trypanosoma cruzi natural stocks were evaluated during the acute phase and the chronic phase of experimental chagasic infection in BALB/c mice...
  89. ncbi TGF-beta plasma levels in chromoblastomycosis patients during itraconazole treatment
    Jorge Pereira da Silva
    Laboratório de Dermato Imunologia, Universidade do Estado do Pará UEPA, Universidade Federal do Para UFPA, Unidade de Referência em Dermatologia Sanitária do Estado do Pará Dr Marcello Candia MC, Brazil
    Cytokine 51:202-6. 2010
    ..The disease evolves to a chronic state, presenting a suppurative granulomatous dermatitis, combined with variable dermal fibrosis. Pathogenesis of the inflammation and tissue repair in CBM are poorly understood...
  90. ncbi Development of a high-throughput method for the determination of itraconazole and its hydroxy metabolite in human plasma, employing automated liquid-liquid extraction based on 96-well format plates and LC/MS/MS
    Constantinos Kousoulos
    Laboratory of Pharmaceutical Analysis and Bioequivalence Services GLP Compliant, Department of Pharmaceutical Chemistry, School of Pharmacy, University of Athens, Panepistimioupoli Zografou, 157 71, Athens, Greece
    Anal Bioanal Chem 384:199-207. 2006
    ..mass spectrometry (LC/MS/MS) method was developed for the simultaneous quantification of the antifungal drug itraconazole (ITZ) and its coactive metabolite hydroxyitraconazole (OH-ITZ) in human plasma...
  91. ncbi Bioavailability of itraconazole in rats and rabbits after administration of tablets containing solid dispersion particles
    S D Yoo
    College of Pharmacy, Sungkyunkwan University, Kyunggi Do, Korea
    Drug Dev Ind Pharm 26:27-34. 2000
    A tablet dosage form containing solid dispersions of itraconazole (Asd tablets) was prepared by using the spray-drying and wet granulation methods...
  92. ncbi Resistance to itraconazole in Aspergillus nidulans and Aspergillus fumigatus is conferred by extra copies of the A. nidulans P-450 14alpha-demethylase gene, pdmA
    N Osherov
    Division of Pathology and Laboratory Medicine, and Department of Internal Medicine Specialties, Section of Infectious Diseases, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    J Antimicrob Chemother 48:75-81. 2001
    ..We selected for genes that would give resistance to itraconazole following transformation with a high copy genomic library of A. nidulans...
  93. ncbi In vitro evaluation of cytochrome P450-mediated drug interactions between cytarabine, idarubicin, itraconazole and caspofungin
    Dawn E Colburn
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Hematology 9:217-21. 2004
    ..Azole antifungal agents are increasingly used in this context. In vitro assays were performed to assess whether cytochrome P450 (CYP450) enzymes were affected by combinations of cytarabine or idarubicin with itraconazole or caspofungin.
  94. ncbi Cost effectiveness of itraconazole in the prophylaxis of invasive fungal infections
    Robin de Vries
    Groningen Research Institute of Pharmacy, University of Groningen, Groningen, The Netherlands
    Pharmacoeconomics 26:75-90. 2008
    ..As the diagnosis of invasive fungal infections is difficult, effective antifungal prophylaxis is desirable. So far, fluconazole has been the most commonly used...
  95. ncbi Itraconazole/TPGS/Aerosil200 solid dispersions: characterization, physical stability and in vivo performance
    Bernard Van Eerdenbrugh
    Laboratory for Pharmacotechnology and Biopharmacy, K U Leuven, Gasthuisberg O and N2, Herestraat 49, box 921, 3000 Leuven, Belgium
    Eur J Pharm Sci 38:270-8. 2009
    Solid dispersions were successfully prepared by co-spray-drying of TPGS-stabilized itraconazole nanosuspensions with Aerosil200, followed by heat treatment of the powders...
  96. ncbi Microcrystalline cellulose, a useful alternative for sucrose as a matrix former during freeze-drying of drug nanosuspensions - a case study with itraconazole
    Bernard Van Eerdenbrugh
    Laboratory for Pharmacotechnology and Biopharmacy, Leuven, Belgium
    Eur J Pharm Biopharm 70:590-6. 2008
    b>Itraconazole nanosuspensions, stabilized with 10% TPGS (relative to the weight of itraconazole), were transformed into nanoparticulate powders by freeze-drying...
  97. ncbi Exposure to oral S-ketamine is unaffected by itraconazole but greatly increased by ticlopidine
    M A Peltoniemi
    Department of Anesthesiology, Intensive Care, Emergency Care and Pain Medicine, University of Turku and Turku University Hospital, Turku, Finland
    Clin Pharmacol Ther 90:296-302. 2011
    ..of oral S-ketamine with the cytochrome P450 (CYP) 2B6 inhibitor ticlopidine and the CYP3A inhibitor itraconazole. In this randomized, blinded, crossover study, 11 healthy volunteers ingested 0...
  98. ncbi Species distribution and antifungal susceptibility of Candida bloodstream isolates in a tertiary medical center in Israel
    Z Samra
    Department of Clinical Microbiology, Rabin Medical Center, Beilinson Campus, and Sackler School of Medicine, Tel Aviv University, Petach Tikva, 49100, Israel
    Eur J Clin Microbiol Infect Dis 24:592-5. 2005
    ..albicans isolates, in 3.4% of C. parapsilosis isolates, and in 21.4% of C. glabrata isolates. Resistance to itraconazole was detected in 3.2% of C. albicans isolates, in 2.9% of C. tropicalis isolates, in 3.4% of C...
  99. ncbi In meta-analysis itraconazole is superior to fluconazole for prophylaxis of systemic fungal infection in the treatment of haematological malignancy
    A G Prentice
    Br J Haematol 132:656-8; author reply 658-9. 2006
  100. ncbi Clinical study of solid dispersions of itraconazole prepared by hot-stage extrusion
    Karel Six
    Laboratorium voor Farmacotechnologie en Biofarmacie, Campus Gasthuisberg O N, 49 Herestraat, B 3000, K U Leuven, Leuven, Belgium
    Eur J Pharm Sci 24:179-86. 2005
    The aim of this study was to investigate the performance of three new solid dispersion formulations of itraconazole in human volunteers in comparison with Sporanox, the marketed form...
  101. ncbi Comparative cost-effectiveness of posaconazole versus fluconazole or itraconazole prophylaxis in patients with prolonged neutropenia
    Curtis D Collins
    Department of Pharmacy Services, University of Michigan Health System, Ann Arbor, MI 48109, USA
    Am J Health Syst Pharm 65:2237-43. 2008
    A cost-effectiveness analysis was performed to investigate the financial impact of using posaconazole versus fluconazole or itraconazole prophylaxis in patients with prolonged neutropenia.

Research Grants47

  1. Development of a new Imaging Platform for Pharmaceutical and Biomedical applicati
    Lynne S Taylor; Fiscal Year: 2012
    ..Model drugs will include itraconazole and griseofulvin (combined with oral delivery polymers), dexamethasone and naltrexone (combined with ..
  2. Acyclic Cucurbit n uril Molecular Containers for Drug Solubilization and Delivery
    LYLE D ISAACS; Fiscal Year: 2013
    ..g. paclitaxel, clopidogrel, fenofibrate, cinnarizine, itraconazole) as well as drugs in various stages of development by our academic and pharmaceutical collaborators and will be ..
  3. THE YEAST ERGOSTEROL PATHWAY
    Martin Bard; Fiscal Year: 2007
    ..classes, the polyenes (amphotericin B) target plasma membrane-bound sterols and the azoles (fluconazole, and itraconazole) target the cytochrome P450-mediated step, lanosterol C-14 demethylation...
  4. YEAST ERGOSTEROL PATHWAY--NEW ANTIFUNGAL TARGET SITES
    Martin Bard; Fiscal Year: 1999
    ..B) target plasma membrane-bound sterols and the new classes of azoles (ketoconazole, fluconazole, and itraconazole) target the cytochrome P450-mediated step, lanosterol C-14 demethylation...
  5. TRICHOPHYTON AND ASPERGILLUS IMMUNOLOGY AND LUNG DISEASE
    Thomas Platts Mills; Fiscal Year: 1999
    ..trials with systemic antifungals: FIuconazole for patients with asthma who are infected with Trichophyton; and Itraconazole for patients with cystic fibrosis colonized with A. fumigatus...
  6. REDUCED DRUG INTERACTIONS OF AZOLE ANTIFUNGAL DRUGS
    Joseph Gal; Fiscal Year: 2003
    ..The "azoles" ketoconazole and itraconazole are important and widely-used oral antifungal agents, but the use of these drugs is limited by adverse side ..
  7. Planning a Multicenter Oral Itraconazole Trial in Chronic Rhinosinusitis Patients
    Hirohito Kita; Fiscal Year: 2007
    ..a prospective, multicenter, double-blind, placebo-controlled clinical trial to investigate the efficacy of oral itraconazole in patients with CRS with nasal polyps...
  8. Antifungal Drug Resistance in Aspergillus
    Kieren Marr; Fiscal Year: 2004
    ..fumigatus, which appears to have a high degree of resistance to Itraconazole. The studies proposed herein will facilitate our understanding of the clinical significance of a new ..
  9. ADULT AIDS CLINICAL TRIALS GROUP
    Michael Saag; Fiscal Year: 2007
    ..abstract_text> ..
  10. RECENT ADVANCES IN AIDS AND HIV RESEARCH
    Michael Saag; Fiscal Year: 2007
    ..CME credit for attending physicians will be provided. ..
  11. Prevention/diagnosis/fungal infections/transplantation
    Barbara Alexander; Fiscal Year: 2005
    ..This approach will shorten the time from development to clinical implementation in therapeutic trials and guidelines. ..
  12. Sterol Biosynthesis in Trypanosomatid Parasites
    Frederick Buckner; Fiscal Year: 2004
    ..The drugs discovered in this research program will hopefully provide better future treatment for patients with these devastating diseases. ..
  13. Calcineurin and Aspergillus fumigatus Pathogenesis
    WILLIAM STEINBACH; Fiscal Year: 2008
    ..I will also test the non-immunosuppressive calcineurin inhibitor analogs to decrease the total level of immunosuppression and therefore increase the overall antifungal efficacy of exploiting the calcineurin pathway. ..
  14. Detection and Significance of Antifungal Resistance in Oropharyngeal Candidiasis
    Thomas F Patterson; Fiscal Year: 2010
    ..This research is aimed at developing rapid molecular tests to detect yeasts which are resistant to antifungal agents in order to allow early use of more effective therapy. ..
  15. Host-Response Relationships in Patients with Candidemia
    Melissa Johnson; Fiscal Year: 2006
    ....
  16. A pharmacogenetic and pharmacodynamic study of erlotinib
    CHARLES RUDIN; Fiscal Year: 2004
    ..Defining the basis of this toxicity could also promote the development of EGFR-directed agents that may avoid such toxicity or that may be effective in a broader spectrum of cancer patients. ..
  17. Phase I/II Study of MS-275 and 5-Azacytidine in Patients with Advanced Non-Small
    CHARLES RUDIN; Fiscal Year: 2008
    ..If successful, this approach could alter the poor prognosis of individuals with this disease. [unreadable] [unreadable] [unreadable]..
  18. Adrenergic Antagonism During Murine Candidiasis
    Brad Spellberg; Fiscal Year: 2008
    ..For these reasons, the potential for adrenergic antagonism to act as an effective immunotherapy is highly meritorious of investigation in this training application. ..
  19. MELANOGENESIS IN CRYPTOCOCCUS NEOFORMANS
    JOSHUA NOSANCHUK; Fiscal Year: 2002
    ..To explore the structure of melanin using biochemistry, phage display peptide libraries and mAbs; and 4. To use peptides and mAbs to study C. neoformans melanogenesis in vivo and in vitro. ..
  20. MECHANISM OF IL-12 INHIBITION BY CANDIDA ALBICANS
    Mahmoud Ghannoum; Fiscal Year: 2009
    ..Data obtained from these studies will lead to a better understanding of the complex immune response to CA infection and may identify novel prevention/treatment strategies for candidiasis. ..
  21. MOLECULAR TARGETS OF BLOCKING MALARIA TRANSMISSION
    Joseph M Vinetz; Fiscal Year: 2010
    ..falciparum chitinase, PfCHTI, and provide the scientific basis for developing novel potential approaches to interrupting malaria transmission at the vertebrate host-mosquito vector interface. ..
  22. Monoclonal antibodies to inhibit Aspergillus germination
    MARTA L FELDMESSER; Fiscal Year: 2010
    ..It is anticipated that this study will identify fungal molecules important for germination and begin to define their interaction with host immune responses. ..
  23. Antibody Protection in Histoplamosis
    JOSHUA NOSANCHUK; Fiscal Year: 2009
    ..These studies are expected to lead to insights into H. capsulatum pathogenesis and initiate the development of new therapeutic and diagnostic reagents. ..
  24. Dopamine Systems and Neuropsychiatric Changes in HIV/AIDS
    Benjamin B Gelman; Fiscal Year: 2010
    ..The project breaks ground neuroscientifically, as no autopsy study has advanced to a "task specific" behavioral correlation with circuit level anomalies of a specific neurotransmitter system. ..
  25. QUALITY OF LIFE AND RELATIONSHIPS AFTER BMT
    John Wingard; Fiscal Year: 2001
    ..This information is essential to subsequent planning and implementation of relevant, well-aimed interventions to minimize psychosocial disruption and enhance growth in future BMT recipients and their loved ones. ..
  26. Aspergillosis: Engineering Antibody for Diagnosis
    Marta Feldmesser; Fiscal Year: 2006
    ..The availability of reagents that have potential to improve both sensitivity and specificity of galactomannan detection would be a significant advance. ..
  27. TEXAS REPOSITORY FOR AIDS NEUROPATHOGENESIS RESEARCH
    Benjamin Gelman; Fiscal Year: 2007
    ..abstract_text> ..
  28. ADULT AIDS CLINICAL TRIALS UNIT
    Mitchell Goldman; Fiscal Year: 2008
    ..Specialized immunology, virology, and pharmacology laboratories will support this work. ..
  29. Enzyme Targets-Sterol Synthesis-Opportunistic Pathogens
    WILLIAM NES; Fiscal Year: 2004
    ..The results from these studies will facilitate the design of therapeutic strategies aimed to provide species-specific discrimination of inhibition in the ergosterol biosynthetic pathway. ..
  30. IRB Assessment and Education Project
    Richard Johnston; Fiscal Year: 2003
    ..abstract_text> ..
  31. MOLECULAR TOXICOLOGY OF EPOXIDE HYDROLASE
    CURTIS OMIECINSKI; Fiscal Year: 2002
    ....
  32. HIV and the Proteasome in the Aging Human Brain
    Benjamin Gelman; Fiscal Year: 2005
    ..The linkage between brain inflammation and altered neuronal protein turnover could lead to a unifying functional concept of dementia with application to HIV and aging both. ..
  33. MOLECULAR TARGETS OF BLOCKING MALARIA TRANSMISSION
    Joseph Vinetz; Fiscal Year: 2005
    ....
  34. North Carolina Needs Assessment for Oral Cancer Control
    Lauren Patton; Fiscal Year: 2003
    ....
  35. Monoclonal antibodies for invasive aspergillosis
    Marta Feldmesser; Fiscal Year: 2003
    ..To determine the biological activity of MAbs generated in Aim 2 in murine models of invasive aspergillosis. It is anticipated that this study will identify important targets for further investigation. ..
  36. Leptospirosis Transmission in the Peruvian Amazon
    Joseph Vinetz; Fiscal Year: 2006
    ....
  37. Innate Effectors of rAls3p-N Anti-Candida Vaccine
    Brad J Spellberg; Fiscal Year: 2010
    ..PNS 398/2590 (Rev. 11/07) Page - Continuation Format Page ..
  38. Human Reservoirs of Plasmodium vivax Transmission in the Peruvian Amazon
    Joseph M Vinetz; Fiscal Year: 2010
    ..vivax, and provide a rational basis for determining strategies to implement and deploy new transmission- blocking vaccines as one approach towards the future elimination of P. vivax malaria from the Amazon basin. ..
  39. International Leptospirosis Society Meeting 2007
    Joseph Vinetz; Fiscal Year: 2007
    ..unreadable] Outcome of the meeting will be assessed by peer-reviewed publication and trainee publication and[unreadable] career advancement. ..
  40. MYELOPATHY AND NEUROPATHY DURING CHANGING HIV BURDEN
    Benjamin Gelman; Fiscal Year: 2004
    ..Together, the studies we have proposed will provide insights concerning prevalent AIDS morbidities in the HAART era. ..
  41. Biology and Drug Resistance of Candida Biofilms
    Mahmoud Ghannoum; Fiscal Year: 2005
    ..albicans biofilms. By studying biofilm model systems and applying this knowledge to the patient population, we will gain a wealth of data about the biology and drug resistance of C. albicans in biofilms. ..
  42. Pharmacodynamics in Antifungal Resistance
    David Andes; Fiscal Year: 2005
    ..The candidate's goal is to integrate knowledge of antifungal PD and the acquisition of approaches and skills in molecular biology through the completion of this grant. ..
  43. Ultrasensitive FACTT assays for serum biomarkers
    Xiaowei Xu; Fiscal Year: 2008
    ..unreadable] [unreadable] ASSESSMENT: [unreadable] [unreadable] [unreadable]..
  44. Microarray Analysis of Leptospiral Genomes
    Joseph Vinetz; Fiscal Year: 2007
    ..unreadable] [unreadable]..
  45. Genetics of Innate Immunity in Human Leptospirosis in Brazil
    Joseph Vinetz; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable] [unreadable]..
  46. MOLECULAR MECHANISMS OF CYTOCHROME P450 EXPRESSION
    CURTIS OMIECINSKI; Fiscal Year: 2002
    ....